Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156). This designation is for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received bevacizumab and, where eligible, mirvetuximab soravtansine.
The FDA’s decision marks a significant milestone in the development of targeted therapies for one of the most difficult-to-treat forms of gynecologic cancer. The Breakthrough Therapy designation is designed to expedite the development and review of drugs intended to treat serious conditions where preliminary clinical evidence suggests the drug may offer substantial improvement over existing therapies.
A New Frontier in Targeted Treatment
Sofetabart mipitecan is a first-in-class folate receptor alpha (FRα) antibody-drug conjugate (ADC). Unlike previous generations of treatments, this molecule utilizes Lilly’s proprietary “PSARlink” technology a cleavable polysarcosine linker to attach a potent exatecan payload (a topoisomerase I inhibitor) to a humanized monoclonal antibody.
What sets sofetabart mipitecan apart is its ability to target FRα across all expression levels. While earlier FRα-targeting drugs often required high levels of receptor expression to be effective, early data for Lilly’s candidate suggest efficacy regardless of whether the tumor has high, medium, or low FRα levels.
Read More: Eli Lilly Announces Positive Results from Two Phase 3 Studies of Jaypirca at ASH 2025
Promising Clinical Evidence
The Breakthrough Therapy designation is supported by data from a Phase 1a/b first-in-human study. Initial results, which were updated at the 2025 ESMO Congress, demonstrated encouraging clinical activity:
- Response Rates: Among 58 efficacy-evaluable patients, the drug achieved an overall response rate (ORR) of 45% and a disease control rate (DCR) of 74%.
- Breadth of Efficacy: Responses were observed across all dose levels (ranging from 2 mg/kg to 6 mg/kg) and across all levels of FRα expression.
- Heavily Pre-treated Population: Notably, the study included patients who had already progressed on prior mirvetuximab soravtansine, a current standard of care for FRα-high patients.
Safety data also indicated a favorable tolerability profile. Compared to other ADCs in this class, sofetabart mipitecan showed low rates of common side effects such as interstitial lung disease (ILD), peripheral neuropathy, and alopecia, with no significant ocular (eye) toxicity reported.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Addressing the “Platinum-Resistant” Challenge
Ovarian cancer remains the fifth leading cause of cancer death among women in the United States. While many patients respond to initial platinum-based chemotherapy, approximately 70% experience a recurrence. Once the disease becomes “platinum-resistant,” recurring within six months, treatment options become extremely limited.
The Road Ahead: Phase 3 FRAmework-01
Building on this momentum, Lilly has already initiated the global Phase 3 FRAmework-01 trial (NCT07213804). This study will investigate sofetabart mipitecan as a monotherapy in patients with platinum-resistant ovarian cancer (PROC) and in combination with bevacizumab for those with platinum-sensitive disease (PSOC).
Last Modified:
